Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $32.50.Several analysts have commented on BDSX shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Biodesix in a research note on Monday, December 15th. Canaccord Genuity Group set a $20.00 price objective on Biodesix and gave the stock a "buy" rating in a report on Friday, September 19th. Finally, Wall Street Zen raised Biodesix from a "sell" rating to a "hold" rating in a research report on Saturday, November 8th.Check Out Our Latest Analysis on BiodesixInstitutional Inflows and OutflowsA number of institutional investors and hedge funds have recently modified their holdings of BDSX. Birchview Capital LP increased its position in shares of Biodesix by 2.8% in the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company's stock worth $3,586,000 after acquiring an additional 154,937 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Oracle Investment Management Inc. purchased a new stake in Biodesix during the 3rd quarter worth $113,000. Finally, Millennium Management LLC acquired a new stake in Biodesix in the 3rd quarter valued at $113,000. Institutional investors and hedge funds own 20.96% of the company's stock. Biodesix Trading Down 5.8%Shares of BDSX stock opened at $6.69 on Monday. The company has a market capitalization of $53.25 million, a price-to-earnings ratio of -1.20 and a beta of 0.62. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The firm has a 50-day moving average price of $7.41 and a 200 day moving average price of $7.33. Biodesix has a twelve month low of $3.44 and a twelve month high of $32.20. Biodesix (NASDAQ:BDSX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.60) by $0.44. The company had revenue of $21.77 million for the quarter, compared to analysts' expectations of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. Research analysts forecast that Biodesix will post -0.35 earnings per share for the current fiscal year. About Biodesix (Get Free Report)Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards. The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.Featured StoriesFive stocks we like better than BiodesixI Shouldn't Be Sending You ThisDo not delete, read immediatelyHow Long Will $1M Last in Retirement?GOLD ALERTBitcoin is down but your income is about to explodeThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Biodesix Right Now?Before you consider Biodesix, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here